BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Helen Thackray, M.D., FAAP, to the newly created position of chief research and development officer. In this role, Dr. Thackray will be responsible for continuing to build the company’s portfolio of rare disease medicines by developing and advancing the company’s R&D strategy from drug discovery through clinical development
March 19, 2021
· 5 min read